Mechanisms of esophageal cancer metastasis and treatment progress

被引:22
作者
Wang, Yusheng [1 ]
Yang, Wei [2 ]
Wang, Qianyun [2 ]
Zhou, Yong [2 ]
机构
[1] First Peoples Hosp Changzhou, Dept Thorac Surg, Changzhou, Jiangsu, Peoples R China
[2] Kunshan Hosp Tradit Chinese Med, Dept Gastroenterol, Kunshan, Jiangsu, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
metastasis; esophageal cancer; anatomical mechanism; molecular mechanism; chemotherapy; immunotherapy; targeted therapy; SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASIS; TUMOR-ASSOCIATED MACROPHAGES; MATRIX METALLOPROTEINASES; POOR-PROGNOSIS; TGF-BETA; CHEMOTHERAPY RESISTANCE; 1ST-LINE TREATMENT; SUPPRESSOR-CELLS; SIGNALING DRIVES;
D O I
10.3389/fimmu.2023.1206504
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Esophageal cancer is a prevalent tumor of the digestive tract worldwide. The detection rate of early-stage esophageal cancer is very low, and most patients are diagnosed with metastasis. Metastasis of esophageal cancer mainly includes direct diffusion metastasis, hematogenous metastasis, and lymphatic metastasis. This article reviews the metabolic process of esophageal cancer metastasis and the mechanisms by which M2 macrophages, CAF, regulatory T cells, and their released cytokines, including chemokines, interleukins, and growth factors, form an immune barrier to the anti-tumor immune response mediated by CD8+ T cells, impeding their ability to kill tumor cells during tumor immune escape. The effect of Ferroptosis on the metastasis of esophageal cancer is briefly mentioned. Moreover, the paper also summarizes common drugs and research directions in chemotherapy, immunotherapy, and targeted therapy for advanced metastatic esophageal cancer. This review aims to serve as a foundation for further investigations into the mechanism and management of esophageal cancer metastasis.
引用
收藏
页数:18
相关论文
共 187 条
[41]   Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis [J].
Han, Jinmin ;
Wang, Zhongtang ;
Liu, Chengxin .
FUTURE ONCOLOGY, 2021, 17 (17) :2257-2274
[42]   Interleukin 32 Promotes Foxp3+ Treg Cell Development and CD8+ T Cell Function in Human Esophageal Squamous Cell Carcinoma Microenvironment [J].
Han, Li ;
Chen, Shiyu ;
Chen, Zheyi ;
Zhou, Bingqian ;
Zheng, Yingxia ;
Shen, Lisong .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
[43]   Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma [J].
Hara, Hiroki ;
Tahara, Makoto ;
Daiko, Hiroyuki ;
Kato, Ken ;
Igaki, Hiroyasu ;
Kadowaki, Shigenori ;
Tanaka, Yoichi ;
Hamamoto, Yasuo ;
Matsushita, Hisayuki ;
Nagase, Michitaka ;
Hosoya, Yoshinori .
CANCER SCIENCE, 2013, 104 (11) :1455-1460
[44]   Regulation of the anti-tumour immune response by cancer-associated fibroblasts [J].
Harper, James ;
Sainson, Richard C. A. .
SEMINARS IN CANCER BIOLOGY, 2014, 25 :69-77
[45]   Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma [J].
Hassuneh, Mona R. ;
Nagarkatti, Mitzi ;
Nagarkatti, Prakash S. .
LEUKEMIA & LYMPHOMA, 2013, 54 (04) :827-834
[46]   Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study [J].
He, Wenwu ;
Wang, Chenghao ;
Wu, Lei ;
Wan, Gang ;
Li, Baisen ;
Han, Yongtao ;
Li, Haojun ;
Leng, Xuefeng ;
Du, Kunyi ;
Chen, Haijun ;
Wang, Qifeng ;
Peng, Lin .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[47]   MDSC: Markers, development, states, and unaddressed complexity [J].
Hegde, Samarth ;
Leader, Andrew M. ;
Merad, Miriam .
IMMUNITY, 2021, 54 (05) :875-884
[48]   Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma [J].
Higashino, Nobuhide ;
Korna, Yu-ichiro ;
Hosono, Masayoshi ;
Takase, Nobuhisa ;
Okamoto, Maiko ;
Kodaira, Himiko ;
Nishio, Mari ;
Shigeoka, Manabu ;
Kakeji, Yoshihiro ;
Yokozaki, Hiroshi .
LABORATORY INVESTIGATION, 2019, 99 (06) :777-792
[49]   Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial [J].
Hironaka, Shuichi ;
Ueda, Shinya ;
Yasui, Hirofumi ;
Nishina, Tomohiro ;
Tsuda, Masahiro ;
Tsumura, Takehiko ;
Sugimoto, Naotoshi ;
Shimodaira, Hideki ;
Tokunaga, Shinya ;
Moriwaki, Toshikazu ;
Esaki, Taito ;
Nagase, Michitaka ;
Fujitani, Kazumasa ;
Yamaguchi, Kensei ;
Ura, Takashi ;
Hamamoto, Yasuo ;
Morita, Satoshi ;
Okamoto, Isamu ;
Boku, Narikazu ;
Hyodo, Ichinosuke .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) :4438-+
[50]   Clinicopathological and prognostic significance of circulating tumor cells in patients with esophageal cancer: a meta-analysis [J].
Hou, Jinxuan ;
Zou, Kun ;
Yang, Chaogang ;
Leng, Xiaohua ;
Xu, Yu .
ONCOTARGETS AND THERAPY, 2018, 11 :8053-8061